Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TG Therapeutics Inc (TGTX) vs Tapestry, Inc. (TPR) Price & Performance

TG Therapeutics IncTrade
Tapestry, Inc.Trade

Price performance (Past 24H)

Key statistics

TG Therapeutics Inc vs Tapestry, Inc. — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Tapestry, Inc. trades at $154.98 (market cap $32.44B). The key difference: Tapestry, Inc. is far larger — about 4.2× TG Therapeutics Inc's market cap, and Tapestry, Inc. pays a 1% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

TGTXTPR
Market Cap
$7.64B$32.44B
Sector
HealthConsumer Cyclical
52-Week High
$59.06$164.78
52-Week Low
$26.94$95.69
Enterprise Value
$7.84B$35.29B
Dividend Yield
1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Tapestry, Inc.

TPR trades at $154.39, down 6.31% over 24 hours, with a bullish technical outlook supported by moving averages and strong analyst consensus. Recent earnings beats and a 75.61% buy rating highlight positive momentum. The company maintains robust gross margins of 76.18% and ROE of 55.74%, though elevated P/E of 48.95 signals premium valuation. Upcoming Q4 2026 earnings on August 13, 2026, and a $0.40 dividend payment on June 22, 2026, are key near-term catalysts.

Outlook remains favorable with a consensus price target of $190.33, implying 23% upside, driven by earnings growth and AI integration initiatives. Risks include high debt levels, competitive pressures, and sensitivity to consumer spending. Investors should weigh strong profitability against valuation concerns ahead of earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX

About Tapestry, Inc.

Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.

Read more on TPR